Effect Of Once-Weekly Semaglutide on Weight Change and Metabolic Control in People with Type 1 Diabetes-Six-Months Results from the Real-World STEMT Trial

被引：0
|
作者：
Mertens, Jonathan
de Winter, Hennah T.
Mazlom, Hadi
Peiffer, Frida W.
Dirinck, Eveline L.
Bochanen, Niels
Van Gaal, Luc F.
de Block, Christophe
机构：
来源：
DIABETES | 2022年 / 71卷
关键词：
D O I：
10.2337/db22-751-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
751-P
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Real-World Impact of Once-Weekly Injectable Semaglutide on Weight, BMI, and HbA1c Outcomes in Type 2 Diabetes-An Observational Study (PAUSE)
    Amamoo, James
    Doshi, Riddhi P.
    Noone, Joshua
    Xie, Lin
    Gamble, Cory L.
    Guevarra, Mico
    Divino, Victoria
    Chen, Justin
    King, Aaron A.
    DIABETES, 2024, 73
  • [22] Real-world use of once-weekly semaglutide in diverse patient populations with type 2 diabetes: pooled analysis of four SURE studies
    Yale, J. -F.
    Catarig, A. -M.
    Catrina, S. -B.
    Erhan, U.
    Sathyapalan, T.
    Schultes, B.
    Tariq, M.
    Knudsen, S. T.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 230 - 230
  • [23] Real-World Evaluation of Once-Weekly Subcutaneous Semaglutide in Patients with Type 2 Diabetes Mellitus in Spain (SEMA-RW Study)
    Mateos, Irene Caballero
    de Lucas, Maria Dolores Garcia
    Doulatram-Gamgaram, Viyey Kishore
    Moreno-Moreno, Paloma
    Jimenez-Millan, Ana Isabel
    Botana-Lopez, Manuel
    Merino-Torres, Juan Francisco
    Soto-Gonzalez, Alfonso
    Fernandez-Garcia, Jose Carlos
    Morales-Portillo, Cristobal
    NUTRIENTS, 2024, 16 (15)
  • [24] Semaglutide Once-Weekly Persistence and Adherence Versus Other GLP-1 RAs in Patients with Type 2 Diabetes in a US Real-World Setting
    Chioma Uzoigwe
    Yuanjie Liang
    Sarah Whitmire
    Yurek Paprocki
    Diabetes Therapy, 2021, 12 : 1475 - 1489
  • [25] Real-World HbA1c Changes Among Type 2 Diabetes Mellitus Patients Initiating Treatment With a 1.0 mg Weekly Dose of Once-Weekly Semaglutide for Diabetes
    Gronroos, Noelle N.
    Swift, Caroline
    Frazer, Monica S.
    Sargent, Andrew
    Leszko, Michael
    Buysman, Erin
    Alvarez, Sara
    Dunn, Tyler J.
    Noone, Josh
    JOURNAL OF HEALTH ECONOMICS AND OUTCOMES RESEARCH, 2024, 11 (02): : 118 - 124
  • [26] Semaglutide Once-Weekly Persistence and Adherence Versus Other GLP-1 RAs in Patients with Type 2 Diabetes in a US Real-World Setting
    Uzoigwe, Chioma
    Liang, Yuanjie
    Whitmire, Sarah
    Paprocki, Yurek
    DIABETES THERAPY, 2021, 12 (05) : 1475 - 1489
  • [27] Semaglutide Once Weekly In Persons with Type 2 Diabetes: Real-World Analysis of the Colombian Diabetes Registry (COL-REAL 1 Study)
    Mario Balcazar, Carlos
    Zambrano, Jose
    Felipe Garcia, Andres
    Eugenia Casanova, Maria
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2021, 116 : 69 - 70
  • [28] Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups
    Yale, Jean-Francois
    Bodholdt, Ulrik
    Catarig, Andrei-Mircea
    Catrina, Sergiu
    Clark, Alice
    Ekberg, Neda Rajamand
    Erhan, Umut
    Holmes, Patrick
    Knudsen, Soren Tang
    Liutkus, Joanne
    Sathyapalan, Thozhukat
    Schultes, Bernd
    Rudofsky, Gottfried
    BMJ OPEN DIABETES RESEARCH & CARE, 2022, 10 (02)
  • [29] Glycemic Control and Body Weight Reduction with Once-Weekly Semaglutide in Colombian Adults with Type 2 Diabetes: Findings from the COLIBRI Study
    Serpa-Diaz, Dagoberto
    Llanos-Florez, Carlos A.
    Uribe, Ronald Serrano
    de Salazar, Dora I. Molina
    Giraldo-Gonzalez, German C.
    Urina-Triana, Miguel
    Suarez-Rodriguez, Andres F.
    Alzate-Vinasco, Maria A.
    DIABETES THERAPY, 2024, 15 (06) : 1451 - 1460
  • [30] Real-World Glycemic Control after Six Months of Treatment with Exenatide Once Weekly vs. Dulaglutide or Albiglutide in Patients with Type 2 Diabetes
    Unni, Sudhir
    Schauerhamer, Marisa B.
    Ma, Junjie
    Wittbrodt, Eric
    Hurd, Jeff
    Ye, Xiangyang
    Mcadam-Marx, Carrie
    DIABETES, 2017, 66 : A308 - A308
12345